Do You Think You Have High Alcohol Tolerance? Here’s How Liquor Impacts Your Brain Activity

Updated Aug 9, 2024 | 03:00 PM IST

SummaryA recent research sheds light on social drinkers and how even moderate alcohol consumption can impact brain activity, challenging the notion that occasional drinking is harmless.
Liquor Impacting Brain Activity (Credit-Freepik)

Liquor Impacting Brain Activity (Credit-Freepik)

Many of us believe that we are great drinkers and that alcohol does not affect us as much. People who are able to drink without showing any sign of inebriation are known as social drinkers. In short, they are not addicted to alcohol but will not turn down the opportunity to have a good time! While it may seem like it doesn’t affect you, new studies suggest that it is just an illusion, even if you have high tolerance, alcohol affects your cognitive and motor functions more than you think.

The study reveals the below implications and techniques:

  • Researchers used a new MRI technique to precisely measure brain electrical activity.
  • By comparing brain scans before and after drinking, scientists identified specific areas affected by alcohol and how much brain activity slowed down.
  • Participants were chosen to be regular social drinkers without alcohol addiction, ensuring the study focused on the effects of alcohol alone.
  • MRI technology provided reliable data on brain activity changes caused by alcohol consumption.

How does the brain react to alcohol?

The human brain is a complex network of billions of neurons that communicate through electrical impulses. Brain conductivity refers to the efficiency with which these electrical signals travel through brain tissue. It's akin to the speed and clarity of a digital signal through a wire. In layman terms, your brain must function in its peak condition as it is essential for various cognitive processes, including memory, attention, decision-making, and motor control.

Think of it as the foundation for your brain's performance. When brain conductivity is high, information flows smoothly, and that helps your brain in rapid processing and response. On the other hand, low conductivity can hinder cognitive function, leading to slower thinking, impaired memory, and difficulties with coordination.

A study conducted at the Neuroscience Research Australia (NeuRA) and UNSW Science unveiled a startling connection between alcohol consumption and brain conductivity.

What is the connection between alcohol consumption and brain activity?

While many people brush off the effects of alcohol as temporary changes in behaviour, the reality is much more complex. Beyond the obvious impacts on coordination and judgment, alcohol significantly alters brain function. Alcohol dramatically slowed down brain activity, especially in areas responsible for decision-making, planning, and physical coordination. This decline was so significant that it resembled the brain changes seen in normal ageing. This means even one drink could temporarily accelerate the ageing process of your brain.

Alcohol and Brain activity: What does the study Imply?

The implications of this research are far-reaching. It provides compelling evidence that alcohol consumption has a direct and measurable impact on brain function. The discovery that alcohol can significantly reduce brain conductivity opens new avenues for understanding the neurocognitive effects of alcohol abuse and dependence. While you may not feel like alcohol is affecting you and you have a high tolerance, it most definitely changes and affects your decision-making abilities and impulse control.

Furthermore, the MRI technique employed in the study could be a valuable tool for assessing the impact of other substances on the brain and for developing interventions to mitigate alcohol-related brain damage.

End of Article

President Donald Trump Remains In Excellent Health, Says White House

Updated May 30, 2026 | 06:00 PM IST

SummaryPresident Trump remains in excellent health, demonstrating strong cardiac, pulmonary, neurological, and overall physical function, according to Dr. Sean Barbabella, physician to the president.
President Donald Trump Remains In Excellent Health, Says White House

Credit: AP

Putting an end to speculation over US President Donald Trump’s health, the White House has announced that the 79-year-old is in “excellent health”.

Trump underwent his annual medical examination at Walter Reed National Military Medical Center on May 26.

"President Trump remains in excellent health, demonstrating strong cardiac, pulmonary, neurological, and overall physical function," Dr. Sean Barbabella, physician to the president, wrote in the memo, released late Friday evening.

He added that Trump is "fully fit to carry out all duties of the Commander-in-Chief and Head of State."

Trump’s health became a major subject of discussion after photographs at times showed swollen ankles, bruised hands, and a blotchy neck. He has been spotted several times with slurred speech and naps during official meetings.

Shortly after the examination, Trump said that "everything checked out perfectly."

Trump, who turns 80 in June, is the oldest person to assume the presidency. He frequently portrays himself as more energetic and fitter than Joe Biden, his Democratic predecessor, who left office last year at age 82 after facing questions about his fitness for the job.

Barbabella described the assessment as a “comprehensive preventive evaluation,” which included a thorough review of all diagnostic studies and laboratory testing conducted over the past year.

It also included “consultations with twenty-two specialty providers from multiple academic institutions. All aspects of the assessment were performed in accordance with US Preventive Services Task Force recommendations,” he said in the memo.

Also read: ‘Sea Or See?’ Donald Trump's Remark Sparks Fresh Cognitive Health Speculation

Diagnostic Summary

The President’s diagnostic summary showed:

  • Vision is normal.
  • Hearing is intact, and teeth are in very good condition.
  • The thyroid and lymph nodes are normal. An ultrasound of the carotid arteries showed normal results.
  • The lungs and chest demonstrated no abnormalities.
  • Coronary CT angiography demonstrated no arterial obstruction or structural abnormalities of the heart or major vessels.
  • An echocardiogram showed no abnormalities. Cardiac function is normal, and circulation to the extremities remains intact.
  • Gastrointestinal/abdominal and genitourinary examinations were normal.
  • Slight lower leg swelling was noted, with improvement from last year.

Barbabella further said that the medical test also evaluated his hands and “revealed ecchymosis (bruising), consistent with minor soft tissue irritation related to frequent handshaking in the setting of aspirin use for cardiovascular prevention". He added that it is “a common and benign effect of aspirin therapy.”

The examination also found no “suspicious lesions or concerning growths.”

Neurological Health

Read More: Was Trump Sleeping During Oval Office Event? White House Reacts

The President's neurological condition was significantly targeted, with many doctors pointing out that he's suffering from dementia. But the test results, authorized by the President for public release, revealed him to be in “normal mental status".

Further, it showed that his "cranial nerves are intact", and he also has "normal motor strength, sensation, reflexes, gait, and balance.”

Trump also completed the Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder-7 (GAD-7) screenings for depression and anxiety, both of which were "normal".

Cognitive function, assessed using the Montreal Cognitive Assessment (MoCA), was also within normal limits, with a score of 30 out of 30.

Lab Results

Comprehensive laboratory evaluation, including a complete blood count, comprehensive metabolic panel, coagulation profile, D-dimer, B-type natriuretic peptide, and cardiac biomarkers, remained within normal limits, Barbabella said.

End of Article

India Makes Significant Progress In Maternal Care, Nutrition And Child Immunization: NFHS-6

Updated May 29, 2026 | 07:00 PM IST

SummaryNFHS-6 reported encouraging progress in child nutrition indicators, with a significant decline in stunting, severe wasting, and underweight prevalence among children under five years. Coverage of major vaccines such as rotavirus and measles also improved significantly.
India Makes Significant Progress In Maternal Care, Nutrition And Child Immunization: NFHS-6

Credit: PIB

India’s Ministry of Health and Family Welfare (MoHFW) has released the National Family Health Survey-6 (NFHS-6), showing major improvements in maternal healthcare, nutrition, immunization, and family planning across the country.

The nationwide survey, which covered nearly 6.79 lakh households across 715 districts, highlighted stronger healthcare access and improved outcomes for women and children in the country.

Key Findings of NFHS-6

The NFHS-6 was conducted during 2023-24 by MoHFW with the International Institute for Population Sciences (IIPS), Mumbai as the nodal agency.

Maternal Care

NFHS-6 recorded notable gains in maternal and child healthcare services nationwide. Nearly 96 per cent of pregnant women received antenatal care (ANC), while mothers receiving ANC during the first trimester increased from 70.0 per cent to 76.2 per cent.

The percentage of mothers receiving at least four ANC visits also rose from 58.5 per cent to 65.2 per cent, reflecting improved continuity of maternal healthcare services.

Institutional deliveries increased from 88.6 per cent to 90.6 per cent, bringing India closer to universal institutional delivery coverage.

Maternal nutrition indicators also improved significantly. Women consuming iron folic acid supplements for 100 days or more during pregnancy increased from 44.1 per cent to 54.9 per cent. Those consuming supplements for 180 days or more rose from 26.0 per cent to 37.8 per cent.

India Makes Significant Progress In Maternal Care, Nutrition And Child Immunization: NFHS-6

Family Planning

India’s Total Fertility Rate (TFR) remained stable at 2.0, while the Contraceptive Prevalence Rate (CPR) increased from 66.7 per cent to 69.1 per cent.

The findings reflect improved access to family planning services and the continued impact of government programs, including Mission Parivar Vikas.

Child Immunization

India also recorded progress towards universal immunization coverage. Full vaccination coverage among children aged 12-23 months increased from 83.8 per cent to 87.1 per cent based on vaccination cards.

More than 95 per cent of children received vaccinations through public health facilities, highlighting continued trust in the public healthcare system.

Coverage of major vaccines improved significantly. Rotavirus vaccination coverage surged from 36.4 per cent to 85.4 per cent, while coverage of the second dose of measles-containing vaccine increased from 58.6 per cent to 71.8 per cent.

The survey also found improvement in child health indicators. Symptoms of acute respiratory infection (ARI) among children declined from 2.8 per cent to 1.9 per cent, while severe diarrhea prevalence fell to 0.5 per cent.

The gains were attributed to stronger last-mile healthcare delivery, improved cold chain systems, digital tracking through U-WIN, and active community participation under the Universal Immunization Program.

Also read: Ebola: Inside India’s RT-PCR Tests For The Bundibugyo Strain| Explained

Child Nutrition Outcomes

NFHS-6 also reported encouraging progress in child nutrition indicators. More than 95 per cent of children under six months were breastfed during the survey period. The percentage of children breastfed within one hour of birth increased from 41.8 per cent to 50.1 per cent.

Stunting among children under five years declined sharply from 35.5 per cent to 29.3 per cent, indicating improvement in long-term nutritional outcomes.

Severe wasting declined from 7.7 per cent to 5.2 per cent, while underweight prevalence among children under five registered a marginal decline from 32.1 per cent to 31.8 per cent.

Infant and young child feeding practices also improved. Children aged 6-8 months receiving solid or semi-solid food along with breastmilk increased from 45.9 per cent to 59.5 per cent.

End of Article

Bundibugyo Ebola Outbreak: WHO Identifies Experimental Treatments, Vaccines

Updated May 29, 2026 | 05:00 PM IST

Summary​The WHO recommends that all identified products should be used exclusively within clinical trials to generate robust data and ensure safe, ethical, and effective research.
Bundibugyo Ebola Outbreak: WHO Identifies Experimental Treatments, Vaccines

Credit: iStock

Amid the ongoing deadly Ebola outbreak, the World Health Organization (WHO) has identified experimental treatments and vaccine candidates for the Bundibugyo strain, which currently has no approved vaccine or antiviral treatment.

The global health agency convened several expert and advisory groups and recommended prioritizing treatment of Bundibugyo cases with:

  • Mapp Biopharmaceutical's MBP134
  • Regeneron’s maftivimab
  • Gilead Sciences’ antiviral remdesivir

In addition, the WHO also advised evaluating combination therapy using a monoclonal antibody together with remdesivir.

The advisory groups recommended that all identified products should be used exclusively within clinical trials to generate robust data and ensure safe, ethical, and effective research.

Preventive Therapies, Vaccine Candidates

Beyond treatment, the WHO also proposed therapies for the prevention of Bundibugyo cases.

  • For post-exposure prophylaxis among contacts of confirmed and probable cases, the oral antiviral obeldesivir was identified as a priority candidate.

  • The expert groups also identified the single-dose rVSV Bundibugyo vaccine, being developed by the International AIDS Vaccine Initiative (IAVI), as the most promising vaccine candidate.
Also read: Ebola: Inside India’s RT-PCR Tests For The Bundibugyo Strain| Explained

The development of the vaccine is expected to take approximately 7–9 months before it can be assessed through clinical trials for its ability to prevent Bundibugyo disease (BDV).

  • Another vaccine candidate, ChAdOx1 Bundibugyo — being developed by Oxford University and the Serum Institute of India — could potentially become available within 2–3 months for efficacy assessment through a clinical trial. However, additional animal data are still required to support and confirm further prioritization.
Experts noted that a single-dose approach for this candidate could be suitable for contacts of Ebola cases, while a two-dose strategy may be considered for high-risk but unexposed populations such as healthcare workers and frontline responders.

  • The experts also reviewed the potential role of Merck's Ervebo, the only licensed Ebola vaccine currently available.
Ervebo is approved for use during outbreaks caused by the most common Ebola virus species in Africa from the Orthoebolavirus family. However, it is not licensed for the prevention of Bundibugyo disease, and evidence regarding cross-protection against other Ebola virus species remains limited and inconclusive.

The WHO stated that Ervebo should not be used outside carefully designed research settings so that its performance against Bundibugyo disease can be properly assessed.

Meanwhile, Regeneron said in a statement that supplies of maftivimab are already available in the Democratic Republic of Congo, if the WHO decides to utilize the treatment immediately or include it as part of additional studies.

Read More: Donald Trump Says Health Check-Up Went 'Perfectly'

Russian Vaccine For New Strain

Meanwhile, Russia has claimed that its scientists have developed a novel vaccine against a new Ebola strain.

According to Russian Health Minister Murashko, "the vaccine may also protect against the rare Bundibugyo strain linked to the current outbreak in the DR Congo".

It is because the "genetic similarity between this virus variant and the vaccine strain is about 60-70%," Alexander Gintsburg, scientific director of the Gamaleya National Center of Epidemiology and Microbiology, was quoted as saying GxP News.

The rare Bundibugyo strain has so far caused over 900 cases and more than 200 deaths in the Democratic Republic of the Congo and Uganda.

End of Article